Ani Pharmaceuticals (ANIP) Invested Capital (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 11 years of Invested Capital data on file, last reported at $19.3 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 72.41% year-over-year to $19.3 million; the trailing twelve-month figure through Mar 2026 stood at $52.3 million (up 132.51% YoY), and the FY2025 full-year result was $17.3 million, up 88.27% from the prior year.
• Invested Capital rose to $19.3 million in Q1 2026, from $17.3 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $346.9 million in Q1 2022 to a low of $414000.0 in Q1 2024.
• A 5-year average of $105.3 million and a median of $12.3 million in 2023 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital slumped 99.88% in 2024 and surged 2603.62% in 2025, its largest moves.
• Tracing ANIP's Invested Capital over 5 years: stood at $338.5 million in 2022, then sank by 96.38% to $12.3 million in 2023, then fell by 25.22% to $9.2 million in 2024, then jumped by 88.27% to $17.3 million in 2025, then gained by 11.76% to $19.3 million in 2026.
• Business Quant data shows ANIP's Invested Capital at $19.3 million in Q1 2026, $17.3 million in Q4 2025, and $15.2 million in Q3 2025.